Related Experiment Videos

Long-term prognosis for reconstruction of arterial lesions due to arteriosclerosis

The Japanese Journal of Surgery
|September 1, 1979
PubMed

Insights

Arteriosclerosis reconstructive surgery showed a 59% patency rate over 3-8 years. Poor survival rates were linked to hypertension, with aggressive reconstruction potentially beneficial for early-stage hypertension but requiring close monitoring in diabetic patients.

Area of Science:

  • Vascular Surgery
  • Cardiovascular Disease Research
  • Arteriosclerosis Treatment

Background:

  • Arteriosclerosis poses a significant challenge in vascular disease management.
  • Reconstructive surgery is a key intervention for affected limbs.
  • Long-term outcomes and influencing factors require detailed investigation.

Purpose of the Study:

  • To evaluate the long-term patency and survival rates following reconstructive surgery for arteriosclerosis.
  • To identify factors influencing the success of surgical interventions.
  • To assess mortality causes and their correlation with patient characteristics and comorbidities.

Main Methods:

  • Retrospective analysis of 100 limbs from 79 patients undergoing reconstructive surgery for arteriosclerosis.
  • Assessment of overall and long-term patency rates over 3 to 8 years.
  • Correlation analysis between patency/survival rates and various clinical factors (hypertension, diabetes, cholesterol, age, etc.).

Main Results:

  • Overall patency rate was 59% over 3-8 years.
  • Long-term patency depended on run-off arteries, surgical site, and method.
  • Survival rates were 62% at 5 years and 48% at 7 years, significantly lower than the general population.
  • Mortality strongly correlated with hypertension severity, with cardiac and renal failure as primary causes.

Conclusions:

  • Arteriosclerotic reconstructive surgery offers moderate long-term patency but is associated with poor survival.
  • Hypertension is a critical factor affecting both patency and mortality.
  • Aggressive reconstruction may be considered for WHO Stage 2 or lower hypertension, but vigilant cardiovascular monitoring is essential for diabetic patients.

Related Concept Videos